Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat.com BioTech Breakout: MoonLake Up 30% On FDA WinsBy Jeffrey Neal Johnson. First Published: 2/3/2026. In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond the Magnificent Seven, clinical-stage biotech remains one of the few places to find large, event-driven returns that are largely independent of the broader economy. MoonLake Immunotherapeutics (NASDAQ: MLTX) is proving that point in real time. The stock rose roughly 10% in the first trading days of February, pushing its price above $16. This move is part of a broader recovery, with shares up more than 30% over the last month. While volatility is the price of admission in this sector, MoonLake's recent rally is not based on hype. It is driven by concrete regulatory wins that have materially changed the company's outlook. Clearing a Path: The Month of Regulatory Wins The spark for the most recent rally arrived on February 2, 2026, when the U.S. Food and Drug Administration (FDA) granted Fast Track designation to MoonLake's lead drug, sonelokimab, for the treatment of palmoplantar pustulosis (PPP). PPP is a severe, chronic skin condition that causes painful blisters on the palms and soles. There are currently no approved treatments for it in the United States, representing a sizable unmet need. Trump's Next Export Ban Could Reshape the Global Economy
It's not semiconductors, AI chips or quantum computers. But none of those technologies can exist without it. On January 19th, 2026, Trump is expected to ban exports of something every tech company desperately needs—forcing them all to relocate to U.S. soil. See what he's about to ban here… Quick Look - The FDA recently granted Fast Track designation to the company's lead drug for a severe skin condition while clearing the path for a major filing.
- Management maintains a robust balance sheet that provides a cash runway extending well into the future to support ongoing clinical development plans.
- Rising share prices and upcoming data readouts could pressure short sellers who bet against the stock now that the period of uncertainty has passed.
Fast Track often sounds like a buzzword, but it carries tangible benefits. It is a formal status granted by the FDA to drugs that show promise in treating serious conditions and offers two practical advantages: - Access: More frequent meetings with the FDA, reducing the chances of pursuing the wrong development path and saving time and money.
- Speed: Rolling review, which allows the company to submit completed sections of its application as they become ready rather than waiting to file the entire package at once. That can shave months off the timeline to approval and potential revenue.
This news followed an even bigger victory. On January 8, 2026, the company announced the results of a critical Type B meeting with the FDA regarding its primary target, hidradenitis suppurativa (HS). In late 2025, MoonLake's stock plunged after mixed clinical results in HS, and investors feared the FDA might demand a new, costly multi-year trial. Instead, the FDA confirmed that the existing data are sufficient to support a filing. That was a major de-risking event. By clearing the path for HS and granting Fast Track for PPP, the FDA has effectively validated MoonLake's underlying nanobody platform. These molecules are smaller than traditional antibodies, enabling better penetration of inflamed tissue. Wins across multiple diseases suggest the platform is functional, transforming MoonLake from a high-risk gamble into a company with a viable, diversified pipeline. Cash Is King: Funded Through 2027 Experienced biotech investors often expect dilution when a small biotech's stock rises: companies frequently issue new shares after price surges to raise capital, which dilutes existing shareholders. MoonLake, however, is in a relatively strong position. According to its third-quarter 2025 financial report, the company holds roughly $380.5 million in cash, cash equivalents, and short-term securities. In drug development, cash equals time. At its current burn rate, MoonLake's runway extends into the second half of 2027. This financial stability is a key pillar of the bull case. It means the company has capital to complete regulatory filings and potentially reach commercialization without immediately returning to the market for more funding. Management can concentrate on execution rather than fundraising, reducing the near-term risk of a dilutive secondary offering that could knock the share price down. Skeptics vs. Momentum: The Setup for a Rally Despite regulatory progress and a healthy cash balance, skepticism remains. As of mid-January 2026, short interest in MoonLake had risen to approximately 12.7% of the available shares. Short sellers, who bet against a stock, likely built those positions during the company's struggles late in 2025. They are positioned for operational setbacks or dilution. But the recent FDA updates undermine that bearish thesis. That creates a potentially combustible setup. If positive news continues and the stock rises, short sellers will incur losses and may be forced to cover by buying shares, which in turn pushes the price higher. With about 12.7% of the float sold short, there is meaningful potential for a short-covering squeeze if momentum persists. Investor Day Preview: The Next Big Mover The recent rally may be only the opening act. MoonLake has scheduled an Investor Day on February 23, 2026, which could provide the next catalyst. The event will highlight a data readout from the Phase 2 S-OLARIS trial testing sonelokimab in axial spondyloarthritis (axSpA), a form of spine-affecting arthritis. A positive readout would add a third indication to the drug's profile, further validating its cross-disease potential. Looking ahead, the company expects to release 52-week HS data in the second quarter of 2026. The main milestone will be submission of a Biologics License Application (BLA) in the second half of the year. Risk, Reward, and Regulatory Alpha MoonLake Immunotherapeutics has navigated a valley of death that ends many young biotech stories. By securing a clear path to approval for HS and Fast Track status for PPP, the company has materially de-risked its profile. Risks around commercial execution and competition remain, but the combination of regulatory clarity, a solid balance sheet, and a skeptical market positioned for a squeeze make MoonLake a notable story in 2026. For investors seeking idiosyncratic growth, MoonLake Immunotherapeutics is worth watching closely this year.
| 
Post a Comment
Post a Comment